Harnessing the natural machinery of the lysosome

Scroll down

Pioneering the next frontier of extracellular protein degradation

We are harnessing the natural machinery of the lysosome to develop oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD)

Led by a highly experienced team of pharma and biotech industry leaders and backed by a syndicate of leading European investors - Gilde Healthcare Partners, Inkef Capital, Novo Seeds and MP Healthcare Venture Management – we are extending the potential of protein degradation to target extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, proprietary technology platform which targets lysosome receptors, and has the potential to revolutionise the field of TPD.

Latest news

Join us

We’re always looking for talented individuals who are driven by a deep commitment to scientific excellence and the desire to bring innovative therapies to patients in need.

Check back here for updates on available positions.

© Draupnir Bio